Chronic ocular graft-versus-host disease is a frequent and potentially sight-threatening complication of allogeneic hematopoietic stem cell transplantation. Dry eye is a major manifestation within a broader disorder involving lacrimal and meibomian glands, conjunctiva, corneal epithelium, and sensory nerves. This narrative review examines clinical assessment, tissue injury, and treatment, with particular attention to recent experimental and translational studies. Human ocular evidence is distinguished from systemic chronic graft-versus-host disease outcomes, findings in other dry-eye populations, and preclinical observations. Single-cell profiling and experimental studies implicate altered epithelial–immune interactions, regulated cell death, oxidative stress, and fibrotic remodeling. Their relevance to treatment selection in patients remains to be established. Clinical care combines tear replacement and conservation, local immunomodulation, epithelial protection, management of meibomian gland dysfunction, and visual rehabilitation. Systemic treatment decisions require separate consideration of ocular activity and other organ involvement. We propose a framework that relates inflammatory activity, structural damage, and dominant ocular traits to management options. This framework is an author-proposed conceptual synthesis, not a validated staging system or treatment algorithm. Small cohorts, inconsistent definitions, attrition, and concurrent therapies limit comparative conclusions. Future trials need standardized ophthalmic endpoints, assessment of treatment burden, and validation of biomarkers before these can guide individual treatment decisions.